Stoke Therapeutics (STOK) Other Non-Current Liabilities (2021 - 2026)

Stoke Therapeutics' Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $991000.0 for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 47.12% year-over-year to $991000.0; the TTM figure through Mar 2026 stood at $991000.0 (down 47.12% YoY), while the FY2025 annual figure was $1.1 million, down 53.95% from the prior year.
• Other Non-Current Liabilities was $991000.0 for Q1 2026 at Stoke Therapeutics, down from $1.1 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $4.9 million in Q4 2023 to a low of $959000.0 in Q3 2023.
• Historically, Other Non-Current Liabilities has averaged $2.6 million across 5 years, with a median of $2.5 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities plunged 73.43% in 2023, then surged 218.04% in 2024.
• A 5-year view of Other Non-Current Liabilities shows it stood at $3.0 million in 2022, then surged by 64.56% to $4.9 million in 2023, then slumped by 49.26% to $2.5 million in 2024, then sank by 53.95% to $1.1 million in 2025, then dropped by 13.15% to $991000.0 in 2026.
• The last three Other Non-Current Liabilities figures came in at $991000.0 (Q1 2026), $1.1 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.